Canaccord Genuity Maintains a 'Buy' on LeMaitre Vascular (LMAT); Mixed Q1
Tweet Send to a FriendGet Alerts LMAT Hot Sheet
Price: $6.71 +0.75%
Rating Summary:
1 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 12 | New: 30
Rating Summary:
1 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 12 | New: 30
Trade LMAT Now!
Canaccord Genuity maintains a 'Buy' on LeMaitre Vascular (NASDAQ: LMAT) price target lowered to $7.00.
Analyst, Jason R. Mills, said, "Revenue beat expectations, while operating income was lower than expected owing to weak gross margin as LMAT is still working through manufacturing inefficiencies with AlboGraft. Revenue guidance was lowered by $500K due to AlboGraft being off the market in UK and France. Encouragingly, the quarter was clean on the P&L– there were no restructuring/impairment charges – as the company has completed its key strategic initiatives that began in 2011. Revised guidance still calls for organic growth of 8%, which is decent for a med tech company in this macro environment. Given LMAT’s history, we think that it’s likely that complementary revenue will be added via acquisition, which is not in our model."
For an analyst ratings summary and ratings history on LeMaitre Vascular click here. For more ratings news on LeMaitre Vascular click here.
Shares of LeMaitre Vascular closed at $5.35 yesterday, with a 52 week range of $5.03-$7.50.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Analyst, Jason R. Mills, said, "Revenue beat expectations, while operating income was lower than expected owing to weak gross margin as LMAT is still working through manufacturing inefficiencies with AlboGraft. Revenue guidance was lowered by $500K due to AlboGraft being off the market in UK and France. Encouragingly, the quarter was clean on the P&L– there were no restructuring/impairment charges – as the company has completed its key strategic initiatives that began in 2011. Revised guidance still calls for organic growth of 8%, which is decent for a med tech company in this macro environment. Given LMAT’s history, we think that it’s likely that complementary revenue will be added via acquisition, which is not in our model."
For an analyst ratings summary and ratings history on LeMaitre Vascular click here. For more ratings news on LeMaitre Vascular click here.
Shares of LeMaitre Vascular closed at $5.35 yesterday, with a 52 week range of $5.03-$7.50.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Morgan Stanley Maintains Bullish Stance on Walter Energy (WLT)
- Deutsche Bank Sees Upside in AIG (AIG) Stock
- Goldman Sachs Maintains Buy on Signet Jewelers (SIG)
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS View, Analyst PT Change
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
